Notwithstanding many setbacks, numerous MDM2 inhibitors have now progressed into late-phase medical advancement. New techniques have also been designed to boost the efficacy of MDM2 inhibitors and to mitigate their on-focus on toxicity. During this critique, we summarize the progress and challenges in the event of the MDM2 specific therapy. https://omard086vbf0.wikipowell.com/user